BioXcel Therapeutics Announces Update On NIDA-Funded Trial of BXCL501 For Potential Treatment of Opioid Use Disorder; Columbia University-Led Trial Expected To Add Fourth Site To Target Completion Of 4-Arm, 160-Patient Trial In 2024
Portfolio Pulse from Benzinga Newsdesk
BioXcel Therapeutics has announced an update on the NIDA-funded trial of BXCL501 for potential treatment of opioid use disorder. The trial, led by Columbia University, is expected to add a fourth site and aims to complete the 4-arm, 160-patient trial in 2024.
November 06, 2023 | 1:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BioXcel Therapeutics' update on the NIDA-funded trial of BXCL501 could potentially impact the company's stock. The addition of a fourth site and the target completion date in 2024 could influence investor sentiment.
The news directly pertains to BioXcel Therapeutics and its product BXCL501. The progress of the trial and its potential success could significantly impact the company's stock. However, as the completion is targeted for 2024, the immediate impact may be neutral as investors may adopt a wait-and-see approach.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100